Nordisk – Page 5 – Talk Bio

Actionable Insights Powered by AI

Alhemo: A Breakthrough in Hemophilia Treatment – FDA Approves Novo Nordisk’s Once-Daily Prophylactic Injection for Hemophilia A and B with Inhibitors

9 months ago talkbio0Tagged Alhemo, Approved, concizumab, Hemophilia A and B, inhibitors, Nordisk, once-daily, Prophylactic treatment, United States Food and Drug Administration

Alhemo, Novo Nordisk, Hemophilia A and B, Inhibitors, FDA Approval, Once-Daily Prophylactic Treatment, Concizumab

Novo Nordisk’s CagriSema Falls Short of Weight Loss Expectations, Highlighting High Investor Expectations

9 months ago talkbio0Tagged CagriSema, Expectations, investor, Nordisk, Obesity, REDEFINE 1 trial, Weight-Loss Agents

CagriSema, Novo Nordisk, Weight Loss Drugs, REDEFINE 1 Trial, Obesity Treatment, Investor Expectations

CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target

9 months ago talkbio0Tagged cagrilintide, CagriSema, Nordisk, Obesity, Phase 3 REDEFINE 1 Trial, semaglutide, Weight Loss

CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide

Novo Nordisk’s Vision for the Future of GLP-1 Therapies: Expanding Beyond Diabetes and Obesity

9 months ago talkbio0Tagged advancements, agonists, Chronic disease, Diabetes Mellitus, Non-Insulin-Dependent, Future, Glucagon-Like Peptide 1, Nordisk, Obesity, semaglutide

GLP-1 agonists, Novo Nordisk, Type 2 diabetes, Obesity, Future treatments, Chronic diseases, Semaglutide, Tirzepatide, Therapeutic advancements

Novo Nordisk and Photys Therapeutics Collaborate on Novel Proximity-Based Therapeutics for Cardiometabolic Diseases

9 months ago talkbio0Tagged cardiometabolic diseases, Nordisk, PHICS, proximity-based, research collaboration, Technology

Novo Nordisk, Photys Therapeutics, Cardiometabolic diseases, Proximity-based therapeutics, PHICS technology, Research collaboration

EU Regulator to Investigate Potential Link Between Ozempic and Rare Eye Condition NAION

9 months ago talkbio0Tagged Agencies, Diabetes, European (ethnic group), Evaluation, NAION, Nordisk, Ozempic, semaglutide

Ozempic, NAION, European Medicines Agency, Novo Nordisk, semaglutide, eye disorder, diabetes drug, investigation

Novo Nordisk Invests $1.2 Billion in Rare Disease Production Facility in Denmark, Creating 400 New Jobs

9 months ago talkbio0Tagged Denmark, Drug Industry, Facility (object), Nordisk, Surgical construction

Novo Nordisk, rare disease production, Denmark, new facility, job creation, pharmaceutical industry

Novo Nordisk Invests $1.2 Billion in New Danish Production Facility for Rare Disease Therapies

9 months ago talkbio0Tagged Denmark, disease drugs, Facility (object), Hemophilia A, Investments, Nordisk, pharmaceutical manufacturing, production

Novo Nordisk, rare disease drugs, Denmark, production facility, investment, hemophilia, pharmaceutical manufacturing

Zepbound Outperforms Wegovy in Weight Loss Trial, Offering Superior Efficacy

9 months ago talkbio0Tagged Clinical Trials, Eli, Eli Lilly, Nordisk, Obesity, semaglutide, Wegovy, Zepbound

Zepbound, Wegovy, weight loss, tirzepatide, semaglutide, clinical trial, obesity medication, Eli Lilly, Novo Nordisk

Novavax Sells Czech Manufacturing Facility to Novo Nordisk for $200 Million

9 months ago talkbio0Tagged cost-cutting, Czech manufacturing, Facility (object), Nordisk, Novavax, Vaccines

Novavax, Novo Nordisk, Czech manufacturing facility, cost-cutting, vaccine pipeline development